Glucocorticoids unleash immune-dependent melanoma control through inhibition of the GARP/TGF-β axis
Preprint 2025 en
Authors
CE
Charles H. Earnshaw
SC
Shih‐Chieh Chiang
AM
Agrin Moeini
Abstract
1 min read
Screening widely used topical treatments in a melanoma model, this study uncovers a surprising role for glucocorticoids in triggering CD8 <sup>+</sup> T cell-dependent tumor control through downregulation of GARP and thus TGF-β signaling. Melanoma patient sample analysis supported these findings suggesting GARP/TGF-β activity functions as a tumor cell-intrinsic immune evasive mechanism, and GARP expression may serve as both a biomarker of poor antitumor immunity and a therapeutic target to improve the response to immunotherapy.
Charles H. Earnshaw, Shih‐Chieh Chiang, Agrin Moeini, Maria A. Koufaki, Eduardo Bonavita, Massimo Russo, Laëtitia Nebot-Bral, Kimberley Hockenhull, Erin Richardson, Charlotte R. Bell, Alexander R. Baker, Robert M. Sellers, Victoria Fife, Matthew Roberts, Theophile Bigirumurame, Caroline Dive, Julia Newton‐Bishop, Jérémie Nsengimana, Christopher Em Griffiths, Santiago Zelenay
Emma Bawden, Teagan Wagner, Jan Schröder, Maike Effern, Daniel Hinze, L. G. M. Newland, Grace H. Attrill, Ariane R. Lee, Sven Engel, David Freestone, Marcela L. Moreira, Elise Gressier, Nathan McBain, Annabell Bachem, Ashraful Haque, Ruining Dong, Angela L. Ferguson, Jarem Edwards, Peter M. Ferguson, Richard A Scolyer, James S. Wilmott, Christopher M. Jewell, Andrëw G. Brööks,
Jinming Yang, Oriana E. Hawkins, Whitney Barham, Pavlo Gilchuk, Mark Boothby, Gregory D. Ayers, Sebastian Joyce, Michael Karin, Fiona E. Yull, Ann Richmond
Jinming Yang, Oriana E. Hawkins, Whitney Barham, Pavlo Gilchuk, Mark Boothby, Gregory D. Ayers, Sebastian Joyce, Michael Karin, Fiona E. Yull, Ann Richmond
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.